GLP-1S
| Vendor | Price | 10mg cost | Updated | Actions |
|---|---|---|---|---|
| Lost Coast Aminos 9.5/10 COA ✓Ships: USCredit/debit card · Zelle Verification & shipping9.5/10 COA ✓Ships: USCredit/debit card · Zelle | $27.00 | $27.00Checked 6 days ago | 6 days ago | Buy GLP-1S from Lost Coast Aminos |
| Vantyx Research 6/10 COA ✓Ships: United States and international destinationsCredit/debit card · Same-day bank payment Verification & shipping6/10 COA ✓Ships: United States and international destinationsCredit/debit card · Same-day bank payment | $29.75 | $29.75Checked aug 15, 2026 | Aug 15, 2026 | Buy GLP-1S from Vantyx Research |
| Pepvida Labs 8/10 COA ✓Ships: USVisa · Mastercard Verification & shipping8/10 COA ✓Ships: USVisa · Mastercard | $30.3010mg package | $30.30Checked 4 days ago | 4 days ago | Buy GLP-1S from Pepvida Labs |
| Puratek Peptides 7/10 COA ✓Ships: USZelle · Cash App Verification & shipping7/10 COA ✓Ships: USZelle · Cash App | $31.46 | $31.46Checked jul 31, 2026 | Jul 31, 2026 | Buy GLP-1S from Puratek Peptides |
| MsAmino 7/10 COA ✓Ships: USVisa · Mastercard Verification & shipping7/10 COA ✓Ships: USVisa · Mastercard | $31.99 | $31.99Checked aug 15, 2026 | Aug 15, 2026 | Buy GLP-1S from MsAmino |
| Elite Edge Biotech 8.5/10 COA ✓Ships: USVisa · Mastercard Verification & shipping8.5/10 COA ✓Ships: USVisa · Mastercard | $34.20 | $34.20Checked jul 28, 2026 | Jul 28, 2026 | Buy GLP-1S from Elite Edge Biotech |
Current market data
GLP-1S Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current whole-package cost to obtain at least 10mg of GLP-1S is $27.00 from Lost Coast Aminos. The median 10mg cost across vendors is $58.09.
- Lowest 10mg cost
- $27.00 Lost Coast Aminos
- Median 10mg cost
- $58.09 One normalized offer per vendor
- Lowest package total
- $18.00 Step One Ventures · package size may differ
- Public COA coverage
- 96% 55 of 57 vendors
What the market shows
PeptidePrices found 127 in-stock listings from 57 vendors. The lowest 10mg cost is 54% below the normalized vendor median.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research details
GLP-1S — research data
Overview
About GLP-1S
Mechanism of action
GLP-1 receptor agonist. Stimulates insulin secretion, inhibits glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling.
Safety profile
Nausea, vomiting, diarrhea, constipation, pancreatitis risk, gallbladder disease, thyroid C-cell tumor risk (theoretical), injection site reactions. · Extensive safety data; GI side effects common but manageable; cardiovascular benefit; thyroid warning animal-only
Storage
Stability & handling
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Personal or family history of medullary thyroid carcinoma (MTC). FDA black-box warning.
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Prior serious hypersensitivity reaction to semaglutide or any excipient.
Research products are not for human use. Looking for clinician-supervised care instead? Compare licensed US telehealth providers, published prices, plan terms, and state availability.
Compare supervised options →Related pages
More on GLP-1S
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The STEP 1 Phase 3 trial (NEJM 2021) showed once-weekly GLP-1S 2.4 mg produced a mean 14.9% body weight reduction vs 2.4% with placebo over 68 weeks in adults with obesity — with 86.4% of participants achieving ≥5% weight loss and over half achieving ≥15%.
- The SELECT cardiovascular outcomes trial (NEJM 2023, n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (HR 0.80) in overweight/obese patients without diabetes who had pre-existing cardiovascular disease — the first anti-obesity drug to show MACE reduction and prompting a new FDA indication.